Pharmaceutical manufacturer GlaxoSmithKline said last week it would pay refunds for 340B overcharges occurring in the first quarter of 2021, including overcharges for blockbuster respiratory drugs Trelegy and Nucala.
The refund notice posted Feb. 2 on the U.S. Health Resources and Services Administration’s (HRSA) Office of Pharmacy Affairs website covers mainly GSK powder formulated inhaled drugs. The list includes Trelegy Ellipta, Anoro Ellipta, Breo Ellipta, and Incruise Ellipta, all inhalers indicated to treat chronic obstructive pulmonary disease; Arnuity Ellipta, an asthma treatment; and Ventolin, indicated for bronchospasm. The refund notice also includes GSK’s injectable drug Nucala for treatment of severe asthma.
Pharmaceutical manufacturer GlaxoSmithKline said last week it would pay refunds for 340B overcharges occurring in the first quarter of 2021, including overcharges for blockbuster respiratory drugs Trelegy and Nucala.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
